CU24496B1 - Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk - Google Patents

Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk

Info

Publication number
CU24496B1
CU24496B1 CU2017000154A CU20170154A CU24496B1 CU 24496 B1 CU24496 B1 CU 24496B1 CU 2017000154 A CU2017000154 A CU 2017000154A CU 20170154 A CU20170154 A CU 20170154A CU 24496 B1 CU24496 B1 CU 24496B1
Authority
CU
Cuba
Prior art keywords
formula
cdk inhibitors
pirazole
amine derivatives
derivatives substituted
Prior art date
Application number
CU2017000154A
Other languages
English (en)
Spanish (es)
Other versions
CU20170154A7 (es
Inventor
Rajeev Goswami
Subhendu Mukherjee
Chetan Pandit
Ramulu Poddutoori
Susanta Samajdar
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of CU20170154A7 publication Critical patent/CU20170154A7/xx
Publication of CU24496B1 publication Critical patent/CU24496B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CU2017000154A 2015-06-04 2016-06-03 Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk CU24496B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2803CH2015 2015-06-04
IN6214CH2015 2015-11-18
PCT/IB2016/053267 WO2016193939A1 (en) 2015-06-04 2016-06-03 Substituted heterocyclyl derivatives as cdk inhibitors

Publications (2)

Publication Number Publication Date
CU20170154A7 CU20170154A7 (es) 2018-07-05
CU24496B1 true CU24496B1 (es) 2021-01-12

Family

ID=57440798

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000154A CU24496B1 (es) 2015-06-04 2016-06-03 Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk

Country Status (20)

Country Link
US (3) US10689347B2 (enExample)
EP (2) EP3302448B1 (enExample)
JP (3) JP6750806B2 (enExample)
KR (1) KR102691467B1 (enExample)
CN (2) CN113773257A (enExample)
AU (3) AU2016272908B2 (enExample)
CA (1) CA2987552A1 (enExample)
CU (1) CU24496B1 (enExample)
DK (1) DK3302448T3 (enExample)
EA (1) EA037236B1 (enExample)
FI (1) FI3302448T3 (enExample)
HR (1) HRP20240101T1 (enExample)
IL (2) IL255960B (enExample)
LT (1) LT3302448T (enExample)
MX (2) MX375639B (enExample)
MY (2) MY198769A (enExample)
PH (1) PH12017502179B1 (enExample)
SI (1) SI3302448T1 (enExample)
WO (1) WO2016193939A1 (enExample)
ZA (1) ZA201800022B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
JP6789962B2 (ja) * 2015-03-09 2020-11-25 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ ＣＤＫ阻害剤としてのピラゾロ［１，５−ａ］［１，３，５］トリアジンとピラゾロ［１，５−ａ］ピリミジン誘導体
EP3302448B1 (en) 2015-06-04 2023-10-25 Aurigene Oncology Limited Substituted heterocyclyl derivatives as cdk inhibitors
GB201617548D0 (en) 2016-10-17 2016-11-30 Linnane Pharma Ab Novel biological factor
TWI703149B (zh) 2017-11-16 2020-09-01 美商美國禮來大藥廠 用於抑制cdk7之化合物
KR20200104873A (ko) 2017-12-06 2020-09-04 린 바이오사이언스, 피티와이 엘티디. 튜불린 억제제
US11472774B2 (en) 2018-02-01 2022-10-18 The University Of Sydney Anti-cancer compounds
SMT202400346T1 (it) * 2018-03-29 2024-11-15 Takeda Pharmaceuticals Co Composto eterociclico
CA3095987A1 (en) * 2018-04-04 2019-10-10 Aurigene Discovery Technologies Limited Substituted pyrazole derivatives as selective cdk12/13 inhibitors
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
CN110590747B (zh) * 2018-06-12 2022-03-22 隆泰申医药科技(南京)有限公司 一种化合物、其制备方法、药物组合物和应用
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
JP2021529740A (ja) 2018-06-29 2021-11-04 キネート バイオファーマ インク． サイクリン依存性キナーゼの阻害剤
UA125427C2 (uk) * 2018-09-17 2022-03-02 Юнґдзин Фарм. Ко., Лтд. Похідні тіазолу і їх фармацевтично прийнятні солі
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2020202001A1 (en) 2019-04-01 2020-10-08 Aurigene Discovery Technologies Limited Substituted 5-cyclopropyl-1h-pyrazol-3-yl-amine derivatives as selective cdk12/13 inhibitors
CN110845474B (zh) * 2019-11-07 2021-01-12 四川大学 一种靶向i型prmt的化合物及其制备方法和应用
CN115485274A (zh) * 2020-03-13 2022-12-16 永进药品株式会社 包含噻唑衍生物或其药学上可接受的盐的用于预防或治疗癌症的药物组合物
WO2021182914A1 (ko) * 2020-03-13 2021-09-16 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
TWI783480B (zh) 2020-05-27 2022-11-11 美商美國禮來大藥廠 用於抑制cdk7之化合物
WO2022084930A2 (en) * 2020-10-22 2022-04-28 Aurigene Discovery Technologies Limited Cancer therapy using a combination of cdk7 inhibitor with an anti-microtubule agent
MX2023007218A (es) * 2020-12-18 2023-07-27 Aurigene Oncology Ltd Cocristal de un inhibidor de cinasa dependiente de ciclina (cdk).
CA3215788A1 (en) * 2021-04-27 2022-11-03 Aurigene Oncology Limited Process for preparing a cdk inhibitor
WO2022249141A2 (en) * 2021-05-28 2022-12-01 Aurigene Discovery Technologies Limited Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent
MX2023015245A (es) * 2021-06-16 2024-01-19 Blueprint Medicines Corp Pirimidinil-pirazoles sustituidos como inhibidores de cdk2.
UY39832A (es) 2021-06-28 2023-01-31 Blueprint Medicines Corp Inhibidores de cdk2
TW202327583A (zh) * 2021-12-06 2023-07-16 美商艾克塞里克斯公司 使用ｃｄｋ７抑制劑治療癌症之方法
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
CN118973401B (zh) 2022-05-11 2025-12-02 株式会社前川制作所 削切装置及工件的削切方法
WO2023224961A1 (en) 2022-05-16 2023-11-23 Exelixis, Inc. Cancer therapy using a combination of a cdk7 inhibitor with an oral serd
CN115093397B (zh) * 2022-06-07 2023-09-05 自贡市第三人民医院 一种用于治疗肿瘤的化合物、合成方法及应用
WO2024066984A1 (zh) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 三并环类衍生物、药物组合物以及应用
WO2024140653A1 (zh) * 2022-12-27 2024-07-04 南京圣和药业股份有限公司 选择性cdk12/13抑制剂及其应用
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57169465A (en) * 1981-04-13 1982-10-19 Showa Denko Kk Pyrazole derivative, its preparation and herbicide
AU4166400A (en) 1999-02-11 2000-08-29 Cor Therapeutics, Inc. Alkenyl and alkynyl compounds as inhibitors of factor xa
BR0013143A (pt) 1999-08-12 2002-06-11 Pharmacia Italia Spa Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
KR100423899B1 (ko) 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
EE05405B1 (et) * 2000-08-10 2011-04-15 Pharmacia Italia S.P.A. Kinaasi inhibiitoritena toimivad bitskloprasoolid, nende valmistamismeetod, kasutamine ja neid sisaldavad farmatseutilised kompositsioonid
JP2004517840A (ja) * 2000-11-27 2004-06-17 フアルマシア・イタリア・エツセ・ピー・アー フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用
US6455559B1 (en) 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
DE10148618B4 (de) * 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
JP4553899B2 (ja) 2003-08-21 2010-09-29 メルク フロスト カナダ リミテツド カテプシンシステインプロテアーゼ阻害剤
JP5507049B2 (ja) 2004-12-30 2014-05-28 アステックス、セラピューティックス、リミテッド 医薬品
JP2008526723A (ja) * 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
JP2008528469A (ja) 2005-01-21 2008-07-31 アステックス・セラピューティクス・リミテッド ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤
GT200600457A (es) 2005-10-13 2007-04-27 Aventis Pharma Inc Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2
EP2089394B1 (en) 2006-10-11 2011-06-29 Nerviano Medical Sciences S.r.l. Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
WO2010002472A1 (en) * 2008-07-02 2010-01-07 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
ATE544063T1 (de) 2008-07-17 2012-02-15 Koninkl Philips Electronics Nv Nanoporenvorrichtung und verfahren zur nukleinsäureanalyse
US8541424B2 (en) 2008-12-23 2013-09-24 Abbott Laboratories Anti-viral compounds
FR2943058B1 (fr) 2009-03-11 2011-06-03 Centre Nat Rech Scient Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
EP2241619A1 (en) * 2009-04-17 2010-10-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Development of fluorescently P-loop labeled kinases for screening of inhibitors
JP6106685B2 (ja) * 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
US10112927B2 (en) * 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2014201073A1 (en) 2013-06-13 2014-12-18 Bristol-Myers Squibb Company Macrocyclic factor viia inhibitors
RU2016111675A (ru) 2013-08-30 2017-10-04 Эмбит Байосайенсиз Корпорейшн Соединения биарилацетамида и способы их применения
CA2926207C (en) 2013-10-21 2022-06-21 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
AU2015240518A1 (en) 2014-04-05 2016-10-20 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
FR3025075A1 (fr) * 2014-08-28 2016-03-04 Oreal Nouveau dispositif de soin et/ou maquillage comprenant une composition d’architecture gel/gel
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3302448B1 (en) * 2015-06-04 2023-10-25 Aurigene Oncology Limited Substituted heterocyclyl derivatives as cdk inhibitors

Also Published As

Publication number Publication date
CN108024970A (zh) 2018-05-11
US20180155293A1 (en) 2018-06-07
EP3302448A4 (en) 2018-11-14
AU2021212016A1 (en) 2021-08-26
LT3302448T (lt) 2024-02-12
JP7033764B2 (ja) 2022-03-11
US10689347B2 (en) 2020-06-23
MX2017015521A (es) 2018-11-09
AU2016272908A1 (en) 2018-01-25
US20180362471A9 (en) 2018-12-20
MY190459A (en) 2022-04-21
AU2021212016B2 (en) 2023-03-09
NZ738825A (en) 2024-09-27
IL286428A (en) 2021-10-31
EP3302448A1 (en) 2018-04-11
JP2020196726A (ja) 2020-12-10
JP7482918B2 (ja) 2024-05-14
HK1255239A1 (zh) 2019-08-09
US20200262793A1 (en) 2020-08-20
CA2987552A1 (en) 2016-12-08
PH12017502179A1 (en) 2018-05-28
WO2016193939A1 (en) 2016-12-08
IL255960B (en) 2021-10-31
MX2020010484A (es) 2020-10-22
KR102691467B1 (ko) 2024-08-02
SI3302448T1 (sl) 2024-03-29
US11174232B2 (en) 2021-11-16
ZA201800022B (en) 2025-08-27
IL255960A (en) 2018-01-31
CN113773257A (zh) 2021-12-10
EP4342540A2 (en) 2024-03-27
MX375639B (es) 2025-03-06
US20230250062A9 (en) 2023-08-10
US12331023B2 (en) 2025-06-17
PH12017502179B1 (en) 2024-07-03
EA037236B1 (ru) 2021-02-25
EP3302448B1 (en) 2023-10-25
JP6750806B2 (ja) 2020-09-02
KR20180041112A (ko) 2018-04-23
MY198769A (en) 2023-09-25
CU20170154A7 (es) 2018-07-05
FI3302448T3 (fi) 2024-01-24
CN108024970B (zh) 2021-10-01
AU2016272908B2 (en) 2021-05-06
HRP20240101T1 (hr) 2024-03-29
EA201890001A1 (ru) 2018-04-30
US20220098156A1 (en) 2022-03-31
JP2022078121A (ja) 2022-05-24
EP4342540A3 (en) 2024-05-29
JP2018516917A (ja) 2018-06-28
DK3302448T3 (da) 2024-02-05
AU2023203524A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
CU24496B1 (es) Derivados de pirazol-3-il-amina sustituidos como inhibidores de cdk
ECSP20067394A (es) Inhibidores de cinasa dependientes de ciclina
CL2017002994A1 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
MX2018009158A (es) Compuestos organicos.
MX2021009673A (es) Moduladores de ror-gamma.
MX2017006832A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
MX2016013050A (es) Compuestos organicos.
CU20160111A7 (es) Compuestos de heterociclilo bicíclico como inhibidores de irak4
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
MX2016011468A (es) Inhibidores de calicreína plasmática humana.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
SV2016005313A (es) Derivados de carboxamida
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2018003930A (es) Inhibidores de calicreína plasmática humana.
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CO2017005806A2 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
AR120158A2 (es) Derivados de indol mono o di sustituidos como inhibidores de la replicación viral del dengue